NASDAQ:FLGT Fulgent Genetics - FLGT Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Fulgent Genetics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $30.15 -0.14 (-0.46%) (As of 03/23/2023 12:00 AM ET) Add Compare Share Share Today's Range$30.00▼$31.3950-Day Range$30.15▼$36.2752-Week Range$28.53▼$65.32Volume151,348 shsAverage Volume239,296 shsMarket Capitalization$890.00 millionP/E Ratio6.61Dividend YieldN/APrice Target$41.67 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability Fulgent Genetics MarketRank™ ForecastAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside38.2% Upside$41.67 Price TargetShort InterestHealthy4.90% of Float Sold ShortDividend StrengthN/ASustainability-0.67Upright™ Environmental ScoreNews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.25) to ($1.53) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.65 out of 5 starsMedical Sector85th out of 986 stocksMedical Laboratories Industry5th out of 26 stocks 3.3 Analyst's Opinion Consensus RatingFulgent Genetics has received a consensus rating of Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $41.67, Fulgent Genetics has a forecasted upside of 38.2% from its current price of $30.15.Amount of Analyst CoverageFulgent Genetics has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted4.90% of the float of Fulgent Genetics has been sold short.Short Interest Ratio / Days to CoverFulgent Genetics has a short interest ratio ("days to cover") of 3.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Fulgent Genetics has recently increased by 5.91%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldFulgent Genetics does not currently pay a dividend.Dividend GrowthFulgent Genetics does not have a long track record of dividend growth. Previous Next 4.1 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreFulgent Genetics has received a 58.06% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Private genetic testing services", "Private infectious disease diagnostics services", and "Private medical laboratory services" products. See details.Environmental SustainabilityThe Environmental Impact score for Fulgent Genetics is -0.67. Previous Next 1.9 News and Social Media Coverage News SentimentFulgent Genetics has a news sentiment score of -0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.35 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Fulgent Genetics this week, compared to 3 articles on an average week.Search Interest61 people have searched for FLGT on MarketBeat in the last 30 days. This is an increase of 336% compared to the previous 30 days.MarketBeat Follows10 people have added Fulgent Genetics to their MarketBeat watchlist in the last 30 days. This is an increase of 67% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Fulgent Genetics insiders have not sold or bought any company stock.Percentage Held by Insiders29.50% of the stock of Fulgent Genetics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions43.22% of the stock of Fulgent Genetics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 2.5 Earnings and Valuation Earnings GrowthEarnings for Fulgent Genetics are expected to grow in the coming year, from ($2.25) to ($1.53) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Fulgent Genetics is 6.61, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 136.06.Price to Earnings Ratio vs. SectorThe P/E ratio of Fulgent Genetics is 6.61, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 153.14.Price to Book Value per Share RatioFulgent Genetics has a P/B Ratio of 0.70. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Fulgent Genetics (NASDAQ:FLGT) StockFulgent Genetics, Inc. is a technology company, which engages in the provision of gene testing and sequencing solutions. It offers genes and panels, known mutation, hereditary cancer, carrier screening, and tumor profiling solutions. The company was founded by Ming Hsieh on May 13, 2016 and is headquartered in Temple City, CA.Read More Receive FLGT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Fulgent Genetics and its competitors with MarketBeat's FREE daily newsletter. Email Address FLGT Stock News HeadlinesMarch 16, 2023 | americanbankingnews.comFulgent Genetics (NASDAQ:FLGT) Research Coverage Started at StockNews.comMarch 14, 2023 | americanbankingnews.comFulgent Genetics (NASDAQ:FLGT) Price Target Cut to $35.00 by Analysts at Piper SandlerMarch 23, 2023 | Behind the Markets (Ad)BREAKING: Tiny biotech successfully treats blindnessThere's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.March 6, 2023 | msn.comLooking Into Fulgent Genetics's Return On Capital EmployedMarch 4, 2023 | finance.yahoo.comEarnings Beat: Fulgent Genetics, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their ModelsMarch 3, 2023 | benzinga.comFulgent Genetics Stock (NASDAQ:FLGT), DividendsMarch 1, 2023 | finance.yahoo.comFulgent Genetics, Inc. (FLGT)March 1, 2023 | msn.comFulgent Genetics Non-GAAP EPS of -$0.48 beats by $0.08, revenue of $67.7M beats by $8.13MMarch 23, 2023 | Behind the Markets (Ad)BREAKING: Tiny biotech successfully treats blindnessThere's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.March 1, 2023 | finance.yahoo.comFulgent Genetics Launches New Beacon787 Expanded Carrier Screening PanelMarch 1, 2023 | finance.yahoo.comFulgent Reports Fourth Quarter and Full Year 2022 Financial ResultsMarch 1, 2023 | finance.yahoo.comFulgent Genetics, Inc. (FLGT) Reports Q4 Loss, Tops Revenue EstimatesMarch 1, 2023 | finance.yahoo.comQ4 2022 Fulgent Genetics Inc Earnings CallFebruary 26, 2023 | finance.yahoo.comThis Medical Play Is Up to the TestFebruary 23, 2023 | finance.yahoo.comFulgent to Participate in the Raymond James & Associates’ 44th Annual Institutional Investors ConferenceFebruary 22, 2023 | seekingalpha.comFulgent Genetics: Attractive Valuation, But I Prefer To Hold For NowFebruary 14, 2023 | finance.yahoo.comFulgent Genetics to Announce Fourth Quarter and Full Year 2022 Financial Results on Tuesday, February 28, 2023January 3, 2023 | finance.yahoo.comFulgent Expands Board of Directors with Addition of Reggie GrovesDecember 23, 2022 | finance.yahoo.comMy Top 7 Strong Conviction Buys for 2023December 8, 2022 | seekingalpha.comAt EV/Sales Below 1x, Fulgent Is UndervaluedDecember 8, 2022 | markets.businessinsider.comWhere Fulgent Genetics Stands With AnalystsDecember 5, 2022 | wsj.comNASDAQ: FLGT Lawsuit Alert: Investors who lost Money with shares of Fulgent Genetics, Inc. (NASDAQ: FLGT) should contact the Shareholders FoundationDecember 2, 2022 | finance.yahoo.comOwning 45% shares,institutional owners seem interested in Fulgent Genetics, Inc. (NASDAQ:FLGT),November 28, 2022 | businesswire.comINVESTIGATION ALERT: Scott+Scott Attorneys at Law LLP Investigates Fulgent Genetics, Inc.’s Directors and Officers for Breach of Fiduciary Duties – FLGTNovember 24, 2022 | finance.yahoo.com1 Green Flag and 1 Red Flag for Fulgent Genetics After EarningsNovember 21, 2022 | benzinga.comFINAL DEADLINE ALERT: The Schall Law Firm Encourages Investors in Fulgent Genetics, Inc. with Losses of $100,000 to Contact the FirmNovember 21, 2022 | benzinga.comCLASS ACTION UPDATE for FLGT, PYPL and FRSH: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of ShareholdersSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive FLGT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Fulgent Genetics and its competitors with MarketBeat's FREE daily newsletter. Email Address FLGT Company Calendar Last Earnings2/28/2023Today3/23/2023Next Earnings (Estimated)5/02/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Medical laboratories Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:FLGT CUSIPN/A CIK1674930 Webwww.fulgentgenetics.com Phone(626) 350-0537Fax626-454-1667Employees1,012Year Founded2011Price Target and Rating Average Stock Price Forecast$41.67 High Stock Price Forecast$45.00 Low Stock Price Forecast$35.00 Forecasted Upside/Downside+38.2%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)$4.56 Trailing P/E Ratio6.61 Forward P/E RatioN/A P/E GrowthN/ANet Income$143.40 million Net Margins23.17% Pretax Margin29.73% Return on Equity11.93% Return on Assets10.80% Debt Debt-to-Equity RatioN/A Current Ratio7.13 Quick Ratio7.13 Sales & Book Value Annual Sales$618.97 million Price / Sales1.44 Cash Flow$6.39 per share Price / Cash Flow4.72 Book Value$43.14 per share Price / Book0.70Miscellaneous Outstanding Shares29,519,000Free Float20,811,000Market Cap$890.00 million OptionableNot Optionable Beta1.61 Social Links Key ExecutivesMing HsiehChairman & Chief Executive OfficerJames XiePresident & Chief Operating OfficerPaul H. KimChief Financial OfficerHarry GaoChief Scientific Officer & Laboratory DirectorLawrence M. WeissChief Medical OfficerKey CompetitorsViridian TherapeuticsNASDAQ:VRDNCastle BiosciencesNASDAQ:CSTLProgenityNASDAQ:PROGCareDxNASDAQ:CDNARadNetNASDAQ:RDNTView All CompetitorsInsiders & InstitutionsETF Managers Group LLCSold 1,592 shares on 3/23/2023Ownership: 0.025%Voya Investment Management LLCSold 8,664 shares on 2/28/2023Ownership: 0.040%Truist Financial CorpBought 13,236 shares on 2/17/2023Ownership: 0.045%State of WyomingBought 2,544 shares on 2/16/2023Ownership: 0.018%Point72 Middle East FZEBought 2,641 shares on 2/16/2023Ownership: 0.009%View All Insider TransactionsView All Institutional Transactions FLGT Stock - Frequently Asked Questions Should I buy or sell Fulgent Genetics stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Fulgent Genetics in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" FLGT shares. View FLGT analyst ratings or view top-rated stocks. What is Fulgent Genetics' stock price forecast for 2023? 3 brokers have issued 1-year target prices for Fulgent Genetics' shares. Their FLGT share price forecasts range from $35.00 to $45.00. On average, they anticipate the company's share price to reach $41.67 in the next twelve months. This suggests a possible upside of 38.2% from the stock's current price. View analysts price targets for FLGT or view top-rated stocks among Wall Street analysts. How have FLGT shares performed in 2023? Fulgent Genetics' stock was trading at $29.78 at the start of the year. Since then, FLGT stock has increased by 1.2% and is now trading at $30.15. View the best growth stocks for 2023 here. Are investors shorting Fulgent Genetics? Fulgent Genetics saw a increase in short interest in the month of February. As of February 28th, there was short interest totaling 908,500 shares, an increase of 5.9% from the February 13th total of 857,800 shares. Based on an average trading volume of 239,200 shares, the short-interest ratio is currently 3.8 days. Currently, 4.9% of the company's shares are short sold. View Fulgent Genetics' Short Interest. When is Fulgent Genetics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 2nd 2023. View our FLGT earnings forecast. How were Fulgent Genetics' earnings last quarter? Fulgent Genetics, Inc. (NASDAQ:FLGT) posted its quarterly earnings data on Tuesday, February, 28th. The company reported ($0.71) EPS for the quarter, topping analysts' consensus estimates of ($0.78) by $0.07. The company earned $67.70 million during the quarter, compared to analysts' expectations of $59.44 million. Fulgent Genetics had a trailing twelve-month return on equity of 11.93% and a net margin of 23.17%. What ETFs hold Fulgent Genetics' stock? ETFs with the largest weight of Fulgent Genetics (NASDAQ:FLGT) stock in their portfolio include Invesco Dynamic Biotechnology & Genome ETF (PBE), SPDR S&P Health Care Services ETF (XHS), ROBO Global Healthcare Technology and Innovation ETF (HTEC), Pacer US Small Cap Cash Cows 100 ETF (CALF), Global X Genomics & Biotechnology ETF (GNOM), ETFMG Treatments Testing and Advancements ETF (GERM), Janus Henderson Small Cap Growth Alpha ETF (JSML) and Invesco S&P SmallCap Health Care ETF (PSCH). What guidance has Fulgent Genetics issued on next quarter's earnings? Fulgent Genetics updated its first quarter 2023 earnings guidance on Tuesday, February, 28th. The company provided EPS guidance of for the period. The company issued revenue guidance of $56.00 million-$56.00 million, compared to the consensus revenue estimate of $60.92 million. What other stocks do shareholders of Fulgent Genetics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Fulgent Genetics investors own include NVIDIA (NVDA), CRISPR Therapeutics (CRSP), Inseego (INSG), NeoGenomics (NEO), Invitae (NVTA), Block (SQ), JD.com (JD), Marvell Technology (MRVL), Teladoc Health (TDOC) and Editas Medicine (EDIT). When did Fulgent Genetics IPO? (FLGT) raised $60 million in an initial public offering (IPO) on Thursday, September 29th 2016. The company issued 4,600,000 shares at $12.00-$14.00 per share. Credit Suisse and Piper Jaffray served as the underwriters for the IPO and Raymond James and BTIG were co-managers. What is Fulgent Genetics' stock symbol? Fulgent Genetics trades on the NASDAQ under the ticker symbol "FLGT." Who are Fulgent Genetics' major shareholders? Fulgent Genetics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Dimensional Fund Advisors LP (2.71%), Pacer Advisors Inc. (1.98%), Geode Capital Management LLC (1.34%), JPMorgan Chase & Co. (1.15%), Morgan Stanley (0.90%) and American Century Companies Inc. (0.81%). Insiders that own company stock include Hanlin Gao, Jian Xie, John C Bolger, Paul Kim and X Cycle LP Tcv. View institutional ownership trends. How do I buy shares of Fulgent Genetics? Shares of FLGT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Fulgent Genetics' stock price today? One share of FLGT stock can currently be purchased for approximately $30.15. How much money does Fulgent Genetics make? Fulgent Genetics (NASDAQ:FLGT) has a market capitalization of $890.00 million and generates $618.97 million in revenue each year. The company earns $143.40 million in net income (profit) each year or $4.56 on an earnings per share basis. How many employees does Fulgent Genetics have? The company employs 1,012 workers across the globe. Does Fulgent Genetics have any subsidiaries? The following companies are subsidiares of Fulgent Genetics: CSI, Cytometry Specialists Inc., FF Gene Biotech, Fulgent Investment Development Limited, Fulgent Therapeutics LLC, and Inform Diagnostics.Read More How can I contact Fulgent Genetics? Fulgent Genetics' mailing address is 4978 SANTA ANITA AVENUE, TEMPLE CITY CA, 91780. The official website for the company is www.fulgentgenetics.com. The company can be reached via phone at (626) 350-0537, via email at nborsje@blueshirtgroup.com, or via fax at 626-454-1667. This page (NASDAQ:FLGT) was last updated on 3/23/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.